🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

39 results for “CNS” Clear

  1. Apremilast, Apremilast, Apremilast

    Amgen Technology (Ireland) UC

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  2. Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

    Pharma Mar S.A.

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  3. TUCATINIB, CAPECITABINE, TUCATINIB, RO7771950, RO7771950, TRASTUZUMAB, CAPECITABINE, TRASTUZUMAB

    Roche Registration Limited

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  4. Transcranial Magnetic stimulation

    CNS Pharmaceuticals

    Gambling Disorder

    phase 3 other active

    1 trial

  5. ALECTINIB

    Roche Registration Limited

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  6. Berubicin

    CNS Pharmaceuticals

    Glioblastoma Multiforme, Adult

    phase 2 small molecule active

    1 trial

  7. Berubicin hydrochloride

    Rani Therapeutics Holdings

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  8. Berubicin hydrochloride, Cecenu® 40 mg Kapsel

    CNS Pharmaceuticals

    Glioblastoma multiforme (GBM)

    phase 2 small molecule active

    1 trial

  9. CNSA-001

    PTC THERAPEUTICS, INC.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  10. CTX-4430

    CNS Pharmaceuticals

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  11. DSM265

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule terminated

    2 trials

  12. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  13. Estradiol , estriol , progesterone

    CNS Pharmaceuticals

    Menopause

    phase 2 small molecule terminated

    1 trial

  14. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  15. MMV390048 40mg

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  16. OZ439

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  17. PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  18. Paclitaxel

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  19. Placebo to match 5-mg PTC518 tablets, Placebo to match 20-mg PTC518 tablets, PTC518, PTC518

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  20. Rozlytrek, Rozlytrek, Rozlytrek

    Roche Registration Limited

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  21. Sertraline+Antibiotic (penicillin/azithromycin)

    CNS Pharmaceuticals

    Pandas

    phase 2 small molecule terminated

    1 trial

  22. [90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

    Pharm Research Associates (UK) Limited

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  23. rTMS (repetitive transcranial magnetic stimulation)

    CNS Pharmaceuticals

    Obsessive-Compulsive Disorder

    phase 2 other active

    1 trial

  24. vitamin C

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources